Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21191567 | 1.00 | FAAH (0.40) | FAAHCNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL21124081 | 1.00 | FAAH (0.40) | FAAHCNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL21191736 | 1.00 | FAAH (0.40) | FAAHCNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL21478368 | 0.98 | FAAH (0.39) | FAAHCNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL21191587 | 0.97 | FAAH (0.37) | FAAHCNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL22024455 | 0.94 | FAAH (0.38) | FAAHCNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL22023840 | 0.94 | FAAH (0.38) | FAAHCNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL22624088 | 0.90 | FAAH (0.34) | FAAHTDP1L3MBTL1CTDSP1 | |
| SCHEMBL21039533 | 0.87 | CNR2 (0.43) | FAAHCNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL21909378 | 0.87 | CNR2 (0.43) | FAAHCNR2CNR1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | FAAH 3196/4885CNR2 2902/4885CNR1 2040/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | FAAH 3196/4885CNR2 2902/4885CNR1 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.